Close Menu

Eli Lilly

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

A Supreme Court decision against drug developers in Sorrell v. IMS Health could potentially hamper how pharmacy benefit managers can use physician prescription data to drive adoption of pharmacogenomically guided products.

The technology uses standard glass chips regionally photopatterned with discrete nanostructured separation materials to integrate all the steps of a given multistage assay. This enables higher throughput and better separation, according to one of its developers.

Advion is opening a new services facility in Indianapolis, and Eli Lilly will transition its drug discovery bioanalytical capability to the firm.

"With genomics, and pharmacogenomics, and all the other aspects of the cancers, we have to think of a different way than the randomized trial," said Patrick Loehrer, interim director of Indiana University's cancer center and a member of FDA's Oncology Drugs Advisory Committee.

Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

The chairman, CEO and founder of Alexandria Real Estate Equities told GenomeWeb Daily News that New York's academic and nonprofit research institutions will be among those who stand to benefit from the life sciences campus, the first phase of which it recently completed on Manhattan's East Side.

At a conference this week, an Eli Lilly official said that increasingly novel test platforms may pose challenges for drug developers in terms of regulatory approval and physician adoption.

Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.

Pages

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.